Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Mizuho Medy Co's Debt-to-EBITDA or its related term are showing as below:
During the past 12 years, the highest Debt-to-EBITDA Ratio of Mizuho Medy Co was 1.09. The lowest was 0.00. And the median was 0.51.
TSE:4595's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.63 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Mizuho Medy Co Debt-to-EBITDA Related Terms
Mizuho Medy Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Mizuho Medy Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mizuho Medy Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mizuho Medy Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mizuho Medy Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mizuho Medy Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Mizuho Medy Co (TSE:4595) has a Debt-to-EBITDA of 0.00 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mizuho Medy Co. According to the industry distribution chart, Mizuho Medy Co ranks #999999 out of 681 companies in the Drug Manufacturers industry.
Is Mizuho Medy Co's Debt-to-EBITDA too high?
Mizuho Medy Co's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Mizuho Medy Co ranks #999999 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mizuho Medy Co has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mizuho Medy Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mizuho Medy Co ranks #999999 out of 681 companies for Debt-to-EBITDA. This places Mizuho Medy Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mizuho Medy Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mizuho Medy Co's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mizuho Medy Co stock overvalued right now?
Based on GuruFocus' analysis, Mizuho Medy Co (TSE:4595) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,424.60, compared to a current price of 円1,701.00 — trading 19.4% above its estimated fair value. The current Debt-to-EBITDA is 0.00. Mizuho Medy Co's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Mizuho Medy Co (TSE:4595), the current Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mizuho Medy Co (TSE:4595) Overvalued in 2026?
Based on GuruFocus' analysis, Mizuho Medy Co stock appears to be overvalued.
The current stock price of 円1,701.00 is trading 19.4% above its estimated GF Value™ of 円1,424.60.
GuruFocus considers Mizuho Medy Co to be Modestly Overvalued.
Key valuation signals for TSE:4595:
Debt-to-EBITDA: 0.00
GF Value™: 円1,424.60 vs. price of 円1,701.00 (19.4% above fair value)
No single metric tells the full story. See the TSE:4595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mizuho Medy Co Ltd engages in research and development, manufacture, and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including a digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.
82GF Score
Get the complete analysis for TSE:4595
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4595 has been successfully added to your 
